If there is one particularly hot topic in the cannabis world in recent years, it is Cannabidiol, better known by its acronym CBD. Today at the heart of a thriving industry and the subject of many scientific studies, the CBD is gaining popularity and recognition after being long overshadowed by the other main cannabis substance:
When we talk about cannabis, we think first drug, joint, psychoactive substance and illicit. For many years now, the light has shifted to highlight another aspect of the plant: its virtues for health.
Defined and demonized for a long time, marijuana is now cultivated for its medicinal properties in many European countries (Germany, Great Britain, Spain, Italy …) as well as in several American states and in Canada. This is called medical or therapeutic cannabis, as opposed to recreational cannabis.
Behind the term medical cannabis are the cannabinoids, chemical compounds that are naturally present in the plant and interact with our bodies to provide a variety of therapeutic and therapeutic effects. psychoactive.
Two of these compounds have been of particular interest for several decades: tetrahydrocannabinol (THC) and cannabidiol (CBD).
Attention, legislative changes in progress!
!! Noting the increase in the number of CBD products sold in France recently, the MILDECA (Interministerial Mission to fight against drugs …) comes, in its publication of June 11, 2018, to affirm its position on these products.
The use and marketing of flowers or leaves of hemp, or products obtained from these parts of the plant, are not allowed, whatever the variety!
• E-liquids and other CBD-based products are banned in France if they contain THC regardless of the amount of THC and if they are not made from varieties and parts of the plant being authorized (cf no CBD from hemp flowers …)
• No therapeutic virtue can be claimed by manufacturers, sellers of products containing CBD, idem for advertising.